Payment overview · 2025
General Payments
$158.10
6 reported records · 4 companies
Healthcare provider profile · identity verified
Andrew Lang
Allopathic & Osteopathic Physicians|Internal Medicine · ROCHESTER, NY · NPI 1831546076
Verified facts
What the public records show
CMS Open Payments records show Andrew Lang received $158.10 in general payments during 2025 across 6 reported records.
Indivior Inc. accounted for 36.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Sublocade.
Indivior Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SUBLOCADE as an associated drug or biological on 22829 records involving 8874 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Sublocade by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $57.39 | 36.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.19 | 34.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.90 | 15.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $21.62 | 13.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $158.10 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $57.39 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.19 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.19 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 179 | exact normalized | Medicare Part D |
| SUBLOCADE sublocade |
2025 | Sublocade | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Indivior Inc. Exact reporting entity; no affiliate inference |
2025 | SUBLOCADE open payments reported associated product |
CMS Open Payments — General Payments 22829 supporting records · 8874 recipient NPIs · example record 1240470773 |
Sublocade · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
179 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 452 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 258 | 64 |
| Gabapentin | Gabapentin | 220 | 45 |
| Lisinopril | Lisinopril | 179 | 54 |
| Ozempic | Semaglutide | 179 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 34 |
| Trazodone Hcl | Trazodone Hcl | 147 | 31 |
| Losartan Potassium | Losartan Potassium | 139 | 38 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 119 | 17 |
| Omeprazole | Omeprazole | 118 | 41 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 111 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 49 |
| Metformin Hcl | Metformin Hcl | 100 | 29 |
| Famotidine | Famotidine | 94 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 92 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 25 |
| Mirtazapine | Mirtazapine | 84 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 83 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 22 |
| Eliquis | Apixaban | 62 | 16 |
| Celecoxib | Celecoxib | 60 | 18 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 57 | 13 |
| Metformin Hcl Er | Metformin Hcl | 55 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 15 |
| Buspirone Hcl | Buspirone Hcl | 54 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 17 |
| Pregabalin | Pregabalin | 49 | 16 |
| Sertraline Hcl | Sertraline Hcl | 49 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 44 | 18 |
| Carvedilol | Carvedilol | 43 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | 14 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 43 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 15 |
| Ibuprofen | Ibuprofen | 41 | 18 |
| Lidocaine | Lidocaine | 41 | 11 |
| Tramadol Hcl | Tramadol Hcl | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Glipizide | Glipizide | 39 | suppressed |
| Simvastatin | Simvastatin | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 12 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Meloxicam | Meloxicam | 29 | 15 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Furosemide | Furosemide | 23 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Sublocade | Buprenorphine | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Buprenorphine | Buprenorphine | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Calcipotriene | Calcipotriene | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $158.10 · 6 records | Indivior Inc. | MOUNJARO, Ozempic, Rybelsus, SUBLOCADE, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Indivior Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error